Vetr lowered shares of Gilead Sciences, Inc. (NASDAQ:GILD) from a strong-buy rating to a buy rating in a report released on Monday morning. They currently have $82.15 price objective on the biopharmaceutical company’s stock.

GILD has been the subject of a number of other research reports. BidaskClub downgraded shares of Gilead Sciences from a buy rating to a hold rating in a research report on Wednesday, August 9th. BMO Capital Markets restated a hold rating and issued a $76.00 price objective (up previously from $75.00) on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Cowen and Company restated an outperform rating and issued a $90.00 price objective on shares of Gilead Sciences in a research report on Wednesday, July 5th. Morgan Stanley reiterated an equal weight rating on shares of Gilead Sciences in a research report on Tuesday, July 11th. Finally, Deutsche Bank AG reiterated a buy rating and set a $81.00 price target (up from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Eleven equities research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $82.09.

Gilead Sciences (NASDAQ GILD) opened at 83.71 on Monday. Gilead Sciences has a one year low of $63.76 and a one year high of $84.13. The firm has a market cap of $109.32 billion, a PE ratio of 9.09 and a beta of 1.21. The stock has a 50 day moving average price of $74.02 and a 200 day moving average price of $69.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm’s revenue was down 8.2% compared to the same quarter last year. During the same quarter last year, the firm earned $3.08 earnings per share. Equities research analysts expect that Gilead Sciences will post $8.73 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This story was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.watchlistnews.com/gilead-sciences-inc-gild-downgraded-by-vetr-inc/1535023.html.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.48%. Gilead Sciences’s dividend payout ratio is presently 22.58%.

In related news, EVP Gregg H. Alton sold 40,000 shares of Gilead Sciences stock in a transaction on Friday, July 21st. The shares were sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the transaction, the executive vice president now owns 137,488 shares in the company, valued at approximately $10,174,112. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the transaction, the executive vice president now owns 102,988 shares in the company, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. Insiders have sold a total of 206,666 shares of company stock valued at $15,223,184 over the last three months. Corporate insiders own 1.30% of the company’s stock.

Several institutional investors have recently bought and sold shares of GILD. Hall Laurie J Trustee raised its position in Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its position in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. raised its position in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares during the last quarter. Penserra Capital Management LLC raised its position in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares during the last quarter. Finally, Webster Bank N. A. raised its position in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares during the last quarter. Institutional investors and hedge funds own 74.04% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.